...CEO of Sanofi (Euronext:SAN; NASDAQ:SNY), onetime FDA Commissioner Mark McClellan and Kim Popovits, chairman, president and CEO of Genomic Health Inc....

...tests to guide decisions throughout the continuum of patient care. In 2019, Exact Sciences acquired Genomic Health Inc....

...System. Parker Institute for Cancer Immunotherapy hired Frederic Pla as COO. He was COO of Genomic Health Inc....

...joined as chief commercial officer in September. Newmark was senior director of medical affairs at Genomic Health Inc....

...of population health sciences at Duke University School of Medicine. Two cancer diagnostic companies -- Genomic Health Inc....
...tumor biomarker tests have already gained increased coverage by conducting prospective trials demonstrating clinical utility. Genomic Health Inc....
...for reimbursement that could encourage investment and speed development.” Steven Shak, Genomic Health In June 2018, Genomic Health...

...its international reach, its position with payers and its sales force, Exact Sciences is acquiring Genomic Health...
...NASDAQ:EXAS), whose revenues have long been tied to its lone marketed colorectal cancer screen, Cologuard. Genomic Health Inc....
...$1.6 billion in 2020 and produce cost synergies of about $25 million within three years. Genomic Health...

...NASDAQ:BMRN) 8/1 Post -$0.10 -$0.09 11% Emergent BioSolutions Inc. (NYSE:EBS) 8/1 Post $0.17 $1.07 -84% Genomic Health Inc....

...NASDAQ:MYL) 5/7 Pre $0.79 $0.96 -18% Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) 5/7 Pre $5.46 $4.67 17% Genomic Health Inc....

...was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc....
...consensus estimates of $3.32. R&D expense of $46.6 million was $8.5 million below Street expectations. Genomic Health...
...The number of Oncotype tests delivered in the quarter was 34,810, up 10% from 3Q17. Genomic Health...

...was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc....
...consensus estimates of $3.32. R&D expense of $46.6 million was $8.5 million below Street expectations. Genomic Health...
...The number of Oncotype tests delivered in the quarter was 34,810, up 10% from 3Q17. Genomic Health...